Summary
Stryker Corporation's second quarter and first six months of 2012 results show a solid increase in net sales and earnings compared to the prior year. Driven by growth in the Neurotechnology and Spine segment and strong performance in the U.S. market, total net sales rose by 2.9% for the quarter and 5.1% year-to-date. This growth was achieved despite some headwinds from foreign currency fluctuations and pricing pressures. The company also demonstrated improved operational efficiency, with gross profit margins expanding. While selling, general, and administrative expenses saw an increase, this was largely attributable to acquisition-related costs and a significant charge related to the OtisKnee device settlement. Excluding these one-time items and other charges, adjusted net earnings and adjusted diluted earnings per share showed robust year-over-year growth, indicating the underlying strength of Stryker's core business operations. The company's liquidity remains strong, with substantial cash and marketable securities, and ample borrowing capacity available.
Financial Highlights
50 data points| Revenue | $2.11B |
| Cost of Revenue | $672.00M |
| Gross Profit | $1.43B |
| R&D Expenses | $116.00M |
| SG&A Expenses | $823.00M |
| Operating Expenses | $989.00M |
| Operating Income | $445.00M |
| Net Income | $325.00M |
| EPS (Basic) | $0.85 |
| EPS (Diluted) | $0.85 |
| Shares Outstanding (Basic) | 381.00M |
| Shares Outstanding (Diluted) | 383.30M |
Key Highlights
- 1Net sales increased by 2.9% to $2,106 million for the three months ended June 30, 2012, and by 5.1% to $4,267 million for the six months ended June 30, 2012, compared to the prior year periods.
- 2Gross profit increased by 7.6% for the quarter and 8.5% for the six months, indicating improved profitability on sales.
- 3Neurotechnology and Spine segment showed strong growth, with net sales up 10.1% for the quarter and 11.2% year-to-date.
- 4U.S. sales demonstrated resilience, increasing by 7.7% for the quarter and 8.0% year-to-date, while international sales experienced a slight decrease in the quarter.
- 5Restructuring charges of $19 million for the quarter and $33 million year-to-date were incurred as part of a workforce reduction initiative.
- 6The company recorded a $33 million charge related to the potential settlement of the OtisKnee device matter.
- 7Adjusted net earnings increased by 6.2% for the quarter and 6.8% for the six months, excluding the impact of acquisition/integration charges, restructuring, and the OtisKnee settlement, demonstrating underlying business strength.